Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer

Simonetta M. Leto(Candiolo Cancer Institute), Andrea Bertotti(University of Turin)

Clinical Cancer Research

January 9, 2023

10.1158/1078-0432.ccr-22-2550

Cited by 44

Related Papers

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

|Nature|2019|1.4k

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

|The Lancet Oncology|2016|1k

A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

|Cancer Discovery|2011|948

The genomic landscape of response to EGFR blockade in colorectal cancer

|Nature|2015|495

Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer

|Nature Communications|2017|322